3SBio gains Verseau's macrophage checkpoint modulators for cancer

With a deal to license macrophage checkpoint modulators, 3SBio Inc. (HKSE:1530) is bypassing the standard roster of T cell targets and jumping to the next wave of immuno-oncology targets. The company is gaining exclusive access to mAb inhibitors against macrophage checkpoints from Verseau Therapeutics Inc. (Boston, Mass.).

Verseau will retain rights to the mAbs outside China, Taiwan, Hong Kong and Macau and will be responsible for discovery and optimization of the mAbs. 3SBio will be responsible for development and commercialization in China and will invest $15 million in Verseau's series B round...